Cargando…

Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19

BACKGROUND: Inflammation plays a major role in coronavirus disease (COVID-19). Factors that convey information about the status of inflammation could predict disease severity and help identify patients prone to clinical deterioration. Here, we aimed to evaluate the predictive value of inflammatory m...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrishami, Alireza, Eslami, Vahid, Arab-Ahmadi, Mehran, Alahyari, Sam, Azhideh, Arash, Sanei-Taheri, Morteza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765511/
https://www.ncbi.nlm.nih.gov/pubmed/35126578
http://dx.doi.org/10.4103/jrms.JRMS_1160_20
_version_ 1784634335246155776
author Abrishami, Alireza
Eslami, Vahid
Arab-Ahmadi, Mehran
Alahyari, Sam
Azhideh, Arash
Sanei-Taheri, Morteza
author_facet Abrishami, Alireza
Eslami, Vahid
Arab-Ahmadi, Mehran
Alahyari, Sam
Azhideh, Arash
Sanei-Taheri, Morteza
author_sort Abrishami, Alireza
collection PubMed
description BACKGROUND: Inflammation plays a major role in coronavirus disease (COVID-19). Factors that convey information about the status of inflammation could predict disease severity and help identify patients prone to clinical deterioration. Here, we aimed to evaluate the predictive value of inflammatory markers on the extent of lung involvement and survival of patients with COVID-19. MATERIALS AND METHODS: Eighty patients with confirmed COVID-19 were enrolled. Demographic, clinical, and laboratory data were collected at admission. All patients underwent chest computed tomography (CT); the extent of lung involvement was assessed by a scoring system. Patients were followed up until death or discharge occurred. Logistic regression analysis was performed to evaluate the association of investigated variables with COVID-19-related death. The association between different variables and CT score was assessed using linear regression model. Receiver operator characteristic curve analysis was applied to identify the predictive value of inflammatory markers and CT score on survival. RESULTS: The mean age of patients was 54.2 ± 15.2 years; 65% were male. Increased neutrophil-to-lymphocyte ratio (β =0.69, odds ratio [OR] =1.50), platelet-to-lymphocyte ratio (β =0.019, OR = 1.01), and decreased lymphocyte to C-reactive protein ratio (LCR) (β = −0.35, OR = 0.62) were significantly associated with a higher CT score and increased odds of death (P < 0.05). Lactate dehydrogenase level was also positively related with extensive lung involvement and death (β =1.15, OR = 1.52, P < 0.05). The LCR threshold for identifying survivors from nonsurvivors was 0.53 (area under curve [AUC] =0.82, 78% sensitivity and 74% specificity). Lung involvement ≥50% on chest CT was an excellent predictor of death (AUC = 0.83, 81% sensitivity and 79% specificity). CONCLUSION: Daily-performed laboratory tests that represent inflammation have great value for predicting the amount of disease burden and risk of mortality. Moreover, their cost-effectiveness and feasibility turn them into ideal prognostic markers.
format Online
Article
Text
id pubmed-8765511
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-87655112022-02-03 Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19 Abrishami, Alireza Eslami, Vahid Arab-Ahmadi, Mehran Alahyari, Sam Azhideh, Arash Sanei-Taheri, Morteza J Res Med Sci Original Article BACKGROUND: Inflammation plays a major role in coronavirus disease (COVID-19). Factors that convey information about the status of inflammation could predict disease severity and help identify patients prone to clinical deterioration. Here, we aimed to evaluate the predictive value of inflammatory markers on the extent of lung involvement and survival of patients with COVID-19. MATERIALS AND METHODS: Eighty patients with confirmed COVID-19 were enrolled. Demographic, clinical, and laboratory data were collected at admission. All patients underwent chest computed tomography (CT); the extent of lung involvement was assessed by a scoring system. Patients were followed up until death or discharge occurred. Logistic regression analysis was performed to evaluate the association of investigated variables with COVID-19-related death. The association between different variables and CT score was assessed using linear regression model. Receiver operator characteristic curve analysis was applied to identify the predictive value of inflammatory markers and CT score on survival. RESULTS: The mean age of patients was 54.2 ± 15.2 years; 65% were male. Increased neutrophil-to-lymphocyte ratio (β =0.69, odds ratio [OR] =1.50), platelet-to-lymphocyte ratio (β =0.019, OR = 1.01), and decreased lymphocyte to C-reactive protein ratio (LCR) (β = −0.35, OR = 0.62) were significantly associated with a higher CT score and increased odds of death (P < 0.05). Lactate dehydrogenase level was also positively related with extensive lung involvement and death (β =1.15, OR = 1.52, P < 0.05). The LCR threshold for identifying survivors from nonsurvivors was 0.53 (area under curve [AUC] =0.82, 78% sensitivity and 74% specificity). Lung involvement ≥50% on chest CT was an excellent predictor of death (AUC = 0.83, 81% sensitivity and 79% specificity). CONCLUSION: Daily-performed laboratory tests that represent inflammation have great value for predicting the amount of disease burden and risk of mortality. Moreover, their cost-effectiveness and feasibility turn them into ideal prognostic markers. Wolters Kluwer - Medknow 2021-11-29 /pmc/articles/PMC8765511/ /pubmed/35126578 http://dx.doi.org/10.4103/jrms.JRMS_1160_20 Text en Copyright: © 2021 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Abrishami, Alireza
Eslami, Vahid
Arab-Ahmadi, Mehran
Alahyari, Sam
Azhideh, Arash
Sanei-Taheri, Morteza
Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19
title Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19
title_full Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19
title_fullStr Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19
title_full_unstemmed Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19
title_short Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19
title_sort prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765511/
https://www.ncbi.nlm.nih.gov/pubmed/35126578
http://dx.doi.org/10.4103/jrms.JRMS_1160_20
work_keys_str_mv AT abrishamialireza prognosticvalueofinflammatorybiomarkersforpredictingtheextentoflunginvolvementandfinalclinicaloutcomeinpatientswithcovid19
AT eslamivahid prognosticvalueofinflammatorybiomarkersforpredictingtheextentoflunginvolvementandfinalclinicaloutcomeinpatientswithcovid19
AT arabahmadimehran prognosticvalueofinflammatorybiomarkersforpredictingtheextentoflunginvolvementandfinalclinicaloutcomeinpatientswithcovid19
AT alahyarisam prognosticvalueofinflammatorybiomarkersforpredictingtheextentoflunginvolvementandfinalclinicaloutcomeinpatientswithcovid19
AT azhideharash prognosticvalueofinflammatorybiomarkersforpredictingtheextentoflunginvolvementandfinalclinicaloutcomeinpatientswithcovid19
AT saneitaherimorteza prognosticvalueofinflammatorybiomarkersforpredictingtheextentoflunginvolvementandfinalclinicaloutcomeinpatientswithcovid19